Glurenorm

Glurenorm is a prescription oral medication that contains the active ingredient gliquidone. The product’s specific strength and dosage form are not disclosed, but it is marketed within the European Union as a sulfonylurea class drug for the management of blood glucose levels in adults with type 2 diabetes mellitus.

Glurenorm is indicated for the treatment of type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient to control blood glucose. It may be used as part of a comprehensive diabetes management plan.

- Improves glycemic control in adults with type 2 diabetes - Can be combined with other antidiabetic agents when needed - May be prescribed when lifestyle modifications alone are inadequate - Used as an alternative to other sulfonylureas in certain patients - Helps reduce fasting and post‑prandial glucose levels

Glurenorm may cause a range of side effects, some of which are more frequently observed while others are rare but serious.

Common: - Mild hypoglycemia (low blood sugar) - Nausea or gastrointestinal discomfort - Headache - Dizziness or light‑headedness - Skin rash or itching

Serious: - Severe hypoglycemia requiring assistance - Allergic reactions such as swelling of the face, lips, or tongue - Hepatic dysfunction indicated by jaundice - Hematologic abnormalities like leukopenia

Before starting Glurenorm, certain health considerations should be reviewed to ensure safe use.

- Assess renal and hepatic function, as impairment may affect drug clearance - Use cautiously in elderly patients who may be more prone to hypoglycemia - Monitor blood glucose regularly to adjust dosage as needed - Avoid use during pregnancy or breastfeeding unless clearly indicated by a physician - Review any history of cardiovascular disease, as sulfonylureas can affect heart function - Ensure patients understand signs of hypoglycemia and how to manage them

Glurenorm can interact with several medications, influencing its efficacy or safety profile.

Avoid: - Concurrent use with other sulfonylureas or insulin, which may increase hypoglycemia risk - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise gliquidone levels - Certain non‑steroidal anti‑inflammatory drugs (NSAIDs) that may potentiate hypoglycemic effects

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms - Thiazide diuretics, which can affect glucose metabolism - Antifungal agents with moderate CYP2C9 inhibition - Oral contraceptives, as hormonal changes may alter glucose control